Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
1,4-Dihydropyridines are regarded as privileged structures for drug design, i.e. they tend to bind to a wide variety of receptor sites. We have shown that upon appropriate manipulation of the substituent groups on a 1,4-dihydropyridine template, high affinity and selectivity for the A(3) subtype of adenosine receptors ('P1 receptors') may be attained. In the present study we have begun to extend this approach to P2 receptors which are activated by ATP and other nucleotides. Nicardipine, a representative dihydropyridine, used otherwise as an L-type calcium channel blocker, was shown to be an antagonist at recombinant rat P2X(2) (IC(50)=25 microM) and P2X(4) (IC(50) approximately 220 microM) receptors expressed in Xenopus oocytes. Thus, this class of compounds represents a suitable lead for enhancement of affinity through chemical synthesis. In an attempt to modify the 1,4-dihydropyridine structure with a predicted P2 receptor recognition moiety, we have replaced one of the ester groups with a negatively charged phosphonate group. Several 4-phenyl-5-phosphonato-1,4-dihydropyridine derivatives, MRS 2154 (2, 6-dimethyl), MRS 2155 (6-methyl-2-phenyl), and MRS 2156 (2-methyl-6-phenyl), were synthesized through three component condensation reactions. These derivatives were not pure antagonists of the effects of ATP at P2X(2) receptors, rather were either inactive (MRS 2156) or potentiated the effects of ATP in a concentration-dependent manner (MRS 2154 in the 0.3-10 microM range and MRS 2155 at >1 microM). Antagonism of the effects of ATP at P2X(2) receptor superimposed on the potentiation was also observed at >10 microM (MRS 2154) or 0.3-1 microM (MRS 2155). Thus, while a conventional dihydropyridine, nicardipine, was found to antagonize rat P2X(2) receptors ninefold more potently than P2X(4) receptors, the effects of novel, anionic 5-phosphonate analogues at the receptor were more complex.
Bianchi,
Pharmacological characterization of recombinant human and rat P2X receptor subtypes.
1999, Pubmed,
Xenbase
Bianchi,
Pharmacological characterization of recombinant human and rat P2X receptor subtypes.
1999,
Pubmed
,
Xenbase
Blakeley,
Effects of nifedipine on electrical and mechanical responses of rat and guinea pig vas deferens.
1981,
Pubmed
Borderies,
Effect of different calcium channel blockers on inhibitory junction potentials and slow waves in porcine ileum.
1997,
Pubmed
Boyer,
Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate.
1998,
Pubmed
Burgard,
P2X receptor-mediated ionic currents in dorsal root ganglion neurons.
1999,
Pubmed
Camaioni,
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.
1998,
Pubmed
Damer,
NF279: a novel potent and selective antagonist of P2X receptor-mediated responses.
1998,
Pubmed
,
Xenbase
Humphreys,
Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues.
1998,
Pubmed
Ingall,
Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.
1999,
Pubmed
Jacobson,
A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.
1998,
Pubmed
,
Xenbase
Jiang,
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.
1997,
Pubmed
Kanjhan,
Distribution of the P2X2 receptor subunit of the ATP-gated ion channels in the rat central nervous system.
1999,
Pubmed
Kim,
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
2001,
Pubmed
,
Xenbase
King,
Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors.
1999,
Pubmed
,
Xenbase
King,
Effects of extracellular pH on agonism and antagonism at a recombinant P2X2 receptor.
1997,
Pubmed
,
Xenbase
Lewis,
2',3'-O-(2,4,6- trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP)--a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels.
1998,
Pubmed
Lynch,
Molecular and functional characterization of human P2X(2) receptors.
1999,
Pubmed
,
Xenbase
Mateo,
Ca2+ signals mediated by P2X-type purinoceptors in cultured cerebellar Purkinje cells.
1998,
Pubmed
Morita,
Synthesis and antihypertensive activities of 1,4-dihydropyridine-5-phosphonate derivatives. I.
1987,
Pubmed
Moro,
Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.
1998,
Pubmed
Nandanan,
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands.
2000,
Pubmed
North,
Nucleotide receptors.
1997,
Pubmed
Pankratov,
A purinergic component of the excitatory postsynaptic current mediated by P2X receptors in the CA1 neurons of the rat hippocampus.
1998,
Pubmed
Parker,
Novel variant of the P2X2 ATP receptor from the guinea pig organ of Corti.
1998,
Pubmed
Soto,
Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors.
1999,
Pubmed
,
Xenbase
Swanson,
ATP-stimulated activation of the mitogen-activated protein kinases through ionotrophic P2X2 purinoreceptors in PC12 cells. Difference in purinoreceptor sensitivity in two PC12 cell lines.
1998,
Pubmed
